Go Pro

EUDA Health (EUDA) Competitors

EUDA Health logo
$14.74 -0.47 (-3.12%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

EUDA vs. XGN, PIII, BNR, PARK, and SERA

Should you buy EUDA Health stock or one of its competitors? MarketBeat compares EUDA Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with EUDA Health include Exagen (XGN), P3 Health Partners (PIII), Burning Rock Biotech (BNR), Park Dental Partners (PARK), and Sera Prognostics (SERA). These companies are all part of the "healthcare" industry.

How does EUDA Health compare to Exagen?

EUDA Health (NASDAQ:EUDA) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

4.4% of EUDA Health shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

EUDA Health has higher earnings, but lower revenue than Exagen. EUDA Health is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EUDA Health$6.82M6.46-$2.77M-$2.40N/A
Exagen$66.57M1.72-$19.95M-$0.89N/A

EUDA Health has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Exagen has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market.

EUDA Health presently has a consensus target price of $55.00, indicating a potential upside of 273.24%. Exagen has a consensus target price of $9.11, indicating a potential upside of 92.01%. Given EUDA Health's higher possible upside, analysts plainly believe EUDA Health is more favorable than Exagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Exagen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90

EUDA Health has a net margin of 0.00% compared to Exagen's net margin of -29.49%. EUDA Health's return on equity of 0.00% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
EUDA HealthN/A N/A N/A
Exagen -29.49%-94.37%-28.96%

In the previous week, EUDA Health had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for EUDA Health and 2 mentions for Exagen. Exagen's average media sentiment score of 1.93 beat EUDA Health's score of 0.96 indicating that Exagen is being referred to more favorably in the news media.

Company Overall Sentiment
EUDA Health Positive
Exagen Very Positive

Summary

Exagen beats EUDA Health on 10 of the 17 factors compared between the two stocks.

How does EUDA Health compare to P3 Health Partners?

EUDA Health (NASDAQ:EUDA) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

EUDA Health presently has a consensus target price of $55.00, indicating a potential upside of 273.24%. P3 Health Partners has a consensus target price of $14.00, indicating a potential upside of 18.44%. Given EUDA Health's higher possible upside, equities analysts plainly believe EUDA Health is more favorable than P3 Health Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

4.4% of EUDA Health shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

EUDA Health has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

EUDA Health has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%. EUDA Health's return on equity of 0.00% beat P3 Health Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
EUDA HealthN/A N/A N/A
P3 Health Partners -8.57%-302.33%-19.99%

In the previous week, P3 Health Partners had 1 more articles in the media than EUDA Health. MarketBeat recorded 4 mentions for P3 Health Partners and 3 mentions for EUDA Health. P3 Health Partners' average media sentiment score of 1.26 beat EUDA Health's score of 0.96 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EUDA Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
P3 Health Partners
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

EUDA Health has higher earnings, but lower revenue than P3 Health Partners. EUDA Health is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EUDA Health$6.82M6.46-$2.77M-$2.40N/A
P3 Health Partners$1.46B0.06-$147.95M-$38.60N/A

Summary

EUDA Health and P3 Health Partners tied by winning 7 of the 14 factors compared between the two stocks.

How does EUDA Health compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and EUDA Health (NASDAQ:EUDA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

EUDA Health has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. EUDA Health's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-11.57% -10.98% -7.33%
EUDA Health N/A N/A N/A

Burning Rock Biotech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, EUDA Health has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 4.4% of EUDA Health shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

EUDA Health has a consensus price target of $55.00, suggesting a potential upside of 273.24%. Given EUDA Health's stronger consensus rating and higher possible upside, analysts clearly believe EUDA Health is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

EUDA Health has lower revenue, but higher earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than EUDA Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.10-$7.92M-$0.82N/A
EUDA Health$6.82M6.46-$2.77M-$2.40N/A

In the previous week, EUDA Health had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for EUDA Health and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat EUDA Health's score of 0.96 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Burning Rock Biotech Very Positive
EUDA Health Positive

Summary

EUDA Health beats Burning Rock Biotech on 10 of the 16 factors compared between the two stocks.

How does EUDA Health compare to Park Dental Partners?

EUDA Health (NASDAQ:EUDA) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, EUDA Health and EUDA Health both had 3 articles in the media. Park Dental Partners' average media sentiment score of 1.12 beat EUDA Health's score of 0.96 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EUDA Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Park Dental Partners
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
EUDA HealthN/A N/A N/A
Park Dental Partners N/A N/A N/A

4.4% of EUDA Health shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

EUDA Health presently has a consensus price target of $55.00, indicating a potential upside of 273.24%. Park Dental Partners has a consensus price target of $21.75, indicating a potential upside of 2.36%. Given EUDA Health's higher probable upside, analysts clearly believe EUDA Health is more favorable than Park Dental Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Park Dental Partners
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
2.75

Park Dental Partners has higher revenue and earnings than EUDA Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EUDA Health$6.82M6.46-$2.77M-$2.40N/A
Park Dental Partners$248.15M0.39-$360KN/AN/A

Summary

Park Dental Partners beats EUDA Health on 6 of the 10 factors compared between the two stocks.

How does EUDA Health compare to Sera Prognostics?

EUDA Health (NASDAQ:EUDA) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

4.4% of EUDA Health shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

EUDA Health presently has a consensus price target of $55.00, indicating a potential upside of 273.24%. Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 208.12%. Given EUDA Health's higher possible upside, equities research analysts clearly believe EUDA Health is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EUDA Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sera Prognostics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

EUDA Health has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

EUDA Health has a net margin of 0.00% compared to Sera Prognostics' net margin of -56,385.97%. EUDA Health's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EUDA HealthN/A N/A N/A
Sera Prognostics -56,385.97%-41.02%-30.95%

EUDA Health has higher revenue and earnings than Sera Prognostics. EUDA Health is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EUDA Health$6.82M6.46-$2.77M-$2.40N/A
Sera Prognostics$80K873.76-$31.93M-$0.65N/A

In the previous week, EUDA Health and EUDA Health both had 3 articles in the media. EUDA Health's average media sentiment score of 0.96 beat Sera Prognostics' score of 0.63 indicating that EUDA Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EUDA Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sera Prognostics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Sera Prognostics beats EUDA Health on 8 of the 15 factors compared between the two stocks.

Get EUDA Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for EUDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EUDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EUDA vs. The Competition

MetricEUDA HealthMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$44.06M$1.74B$6.84B$12.43B
Dividend YieldN/AN/A2.67%6.11%
P/E Ratio-6.1479.5525.8224.32
Price / Sales6.467.22549.62102.11
Price / CashN/A24.7329.0936.93
Price / Book-6.525.7010.986.49
Net Income-$2.77M-$54.76M$3.58B$336.61M
7 Day Performance3.19%5.75%2.85%0.76%
1 Month Performance-18.41%-1.51%0.52%-0.48%
1 Year Performance-78.52%2.69%36.24%30.79%

EUDA Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EUDA
EUDA Health
2.4121 of 5 stars
$14.74
-3.1%
$55.00
+273.2%
-77.8%$44.06M$6.82MN/A2
XGN
Exagen
4.3314 of 5 stars
$4.52
+3.7%
$9.11
+101.6%
-34.6%$105.22M$66.57MN/A220
PIII
P3 Health Partners
3.0979 of 5 stars
$11.14
-7.1%
$14.00
+25.7%
+77.6%$86.87M$1.46BN/A500
BNR
Burning Rock Biotech
1.7813 of 5 stars
$8.52
+12.7%
N/A+168.9%$79.52M$77.16MN/A1,390
PARK
Park Dental Partners
2.6736 of 5 stars
$17.30
-1.4%
$21.75
+25.7%
N/A$79.24M$244.49MN/A1,208

Related Companies and Tools


This page (NASDAQ:EUDA) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners